Conference
Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials
Abstract
Nintedanib is a tyrosine kinase inhibitor used to treat idiopathic pulmonary fibrosis (IPF). We investigated the cardiovascular safety of nintedanib using pooled data from the TOMORROW and INPULSIS trials.Cardiovascular events were assessed post hoc in patients with a history of atherosclerotic cardiovascular disease (CVD) and/or one or more cardiovascular risk factors at baseline ("higher cardiovascular risk") and patients with no history of …
Authors
Noth I; Wijsenbeek M; Kolb M; Bonella F; Moros L; Wachtlin D; Corte TJ
Volume
54
Publisher
European Respiratory Society (ERS)
Publication Date
9 2019
DOI
10.1183/13993003.01797-2018
Conference proceedings
European Respiratory Journal
Issue
3
ISSN
0903-1936